All patients | FE-IgG | P-value | ||
---|---|---|---|---|
Low (<0.020) | High (≥0.020) | |||
No. of patients | 84 | 40 | 44 | |
Age (years) | 55 ± 16 | 52 ± 15 | 58 ± 17 | 0.07 |
Sex (M/F) | 50/34 | 20/19 | 30/15 | 0.18 |
eGFR (ml/min/1.73 m2) | 72 ± 26 | 88 ± 20 | 58 ± 23 | < 0.001 |
eGFR < 60 ml/min/1.73 m2 | 29 (34%) | 5 (13%) | 24 (53%) | <0.001 |
BP ≥140/90 mmHg | 45 (54%) | 13 (34%) | 32 (71%) | 0.001 |
Serum albumin g/L | 23 ± 6 | 25 ± 5 | 22 ± 6 | 0.02 |
ACR mg/mmol | 373 ± 256 | 243 ± 278 | 486 ± 177 | < 0.001 |
FE IgG | 0.052 ± 0.063 | 0.009 ± 0.005 | 0.090 ± 0.066 | < 0.001 |
FE α1m | 0.371 ± 0.409 | 0.124 ± 0.106 | 0.601 ± 0.447 | < 0.001 |
GGS (%) | 10 ± 14 | 6 ± 10 | 13 ± 17 | 0.02 |
TIF score | 1.3 ± 1.3 | 0.7 ± 0.7 | 1.2 ± 0.7 | 0.08 |
Follow-up (months) | 86 ± 50 | 98 ± 51 | 77 ± 48 | 0.055 |
ACE inhibitors treatment | 50 (60%) | 26 (65%) | 24 (55%) | 0.27 |